Roche Diagnostics and Capitalbio have announced their intention to initiate a partnership focused on furthering microarray technologies and products for molecular diagnostic applications.
The partnership plans to focus initially on the research and development of instruments and products to enhance and automate the Roche Nimblegen microarray workflow and the application of this workflow in preventive and personalised diagnostics.
It also plans closer co-operation and collaboration across a broad range of advanced molecular diagnostic assays for clinical diagnostics and medical research, including the use of 454 Life Sciences' next-generation sequencing for medical services.
